Literature DB >> 1533773

Dopamine receptor abnormalities in the striatum and pallidum in tardive dyskinesia: a post mortem study.

G P Reynolds1, J E Brown, J C McCall, A V Mackay.   

Abstract

Dopamine D1 and D2 receptors were determined in brain tissue taken post mortem from schizophrenic patients previously known to have had tardive dyskinesia and yet who had not received neuroleptic drug treatment for over one year prior to death. In comparison with age-matched control subjects, diminished D2 receptor density was observed in striatal regions, while these receptors appeared to be increased in the pallidum, an area of the brain particularly implicated in the production of dyskinesias. D 1 receptors showed similar tendencies to lower numbers in the striatum in tardive dyskinesia.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1533773     DOI: 10.1007/bf01245368

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  10 in total

1.  Alterations in dopaminergic receptors in Huntington's disease.

Authors:  T D Reisine; J Z Fields; L Z Stern; P C Johnson; E D Bird; H I Yamamura
Journal:  Life Sci       Date:  1977-10-15       Impact factor: 5.037

2.  No deficit of pallidal D2 dopamine receptors in Huntington's disease.

Authors:  G P Reynolds; J E Brown; S J Pearson
Journal:  J Neurol Sci       Date:  1990-12       Impact factor: 3.181

3.  Striatal dopamine D2 receptors in tardive dyskinesia: PET study.

Authors:  J Blin; J C Baron; H Cambon; A M Bonnet; B Dubois; C Loc'h; B Mazière; Y Agid
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-11       Impact factor: 10.154

4.  Dopamine receptors and schizophrenia: the neuroleptic drug problem.

Authors:  G P Reynolds; P Riederer; K Jellinger; E Gabriel
Journal:  Neuropharmacology       Date:  1981-12       Impact factor: 5.250

5.  Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases.

Authors:  P Seeman; N H Bzowej; H C Guan; C Bergeron; G P Reynolds; E D Bird; P Riederer; K Jellinger; W W Tourtellotte
Journal:  Neuropsychopharmacology       Date:  1987-12       Impact factor: 7.853

6.  3H-spiperone binding sites in post-mortem brains from schizophrenic patients: relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms.

Authors:  J Kornhuber; P Riederer; G P Reynolds; H Beckmann; K Jellinger; E Gabriel
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

7.  Increased brain dopamine and dopamine receptors in schizophrenia.

Authors:  A V Mackay; L L Iversen; M Rossor; E Spokes; E Bird; A Arregui; I Creese; S H Synder
Journal:  Arch Gen Psychiatry       Date:  1982-09

8.  Chorea and myoclonus in the monkey induced by gamma-aminobutyric acid antagonism in the lentiform complex. The site of drug action and a hypothesis for the neural mechanisms of chorea.

Authors:  A R Crossman; I J Mitchell; M A Sambrook; A Jackson
Journal:  Brain       Date:  1988-10       Impact factor: 13.501

9.  Changes in rat striatal dopamine turnover and receptor activity during one years neuroleptic administration.

Authors:  A Clow; A Theodorou; P Jenner; C D Marsden
Journal:  Eur J Pharmacol       Date:  1980-05-02       Impact factor: 4.432

10.  Abnormal involuntary movements in schizophrenia: are they related to the disease process or its treatment? Are they associated with changes in dopamine receptors?

Authors:  T J Crow; A J Cross; E C Johnstone; F Owen; D G Owens; J L Waddington
Journal:  J Clin Psychopharmacol       Date:  1982-10       Impact factor: 3.153

  10 in total
  4 in total

1.  Selective neurotoxins, chemical tools to probe the mind: the first thirty years and beyond.

Authors:  R M Kostrzewa
Journal:  Neurotox Res       Date:  1999-09       Impact factor: 3.911

2.  Postnatal iron-induced motor behaviour alterations following chronic neuroleptic administration in mice.

Authors:  A Fredriksson; P Eriksson; T Archer
Journal:  J Neural Transm (Vienna)       Date:  2005-08-05       Impact factor: 3.575

3.  Functional consequences of iron overload in catecholaminergic interactions: the Youdim factor.

Authors:  Trevor Archer; Anders Fredriksson
Journal:  Neurochem Res       Date:  2007-08-12       Impact factor: 3.996

4.  Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model.

Authors:  Souha Mahmoudi; Daniel Lévesque; Pierre J Blanchet
Journal:  Mov Disord       Date:  2014-05-16       Impact factor: 10.338

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.